Logo
M

MERIT CRO

126 employees

MERIT is an innovative clinical endpoint expert providing attentive expertise in our therapeutic areas. We partner with CROs, pharma, and biotech companies to deliver reliable endpoint services in global clinical trials. With the acquisition of OSOD, MERIT now offers preclinical research services, enabling a seamless transition from preclinical to clinical phases of drug development. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide. We have a proven track record providing endpoint expertise to 13 of the top 20 global pharmaceutical companies. We prioritize a collaborative, partnership-driven approach for all projects with scalable solutions and personalized attention. If you’re looking for a partner that will bring dedication and expertise to your clinical trial, consider MERIT. Show more Show less

Investor insights

Funding rounds participated in

$1.1M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2012

Funding rounds raised

Total raised

$1.1M

from investors over 1 rounds

M

MERIT CRO raised $1.1M on August 20, 2023

FAQ